PPARG and chronic myelogenous leukemia, BCR-ABL1 positive: Activation of the combination of PPARγ ligands with tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) sensitizes leukemic stem cells to chemotherapy [92].